Find information on thousands of medical conditions and prescription drugs.

Faslodex

Fulvestrant is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects and down-regulates the estrogen receptor. It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Home

Femara

Femring

Filipin

Flagyl

Flarex

Flavoxate

Flecainide

Flexeril

Flomax

Flonase

Flovent

FML

Focalin

Fosamax

Frova

Fuzeon

Read more at Wikipedia.org

• [List your site here Free!]

Hormone trial seeks volunteers - FYI
From OB/GYN News, 10/15/03

Researchers are recruiting for a randomized, double-blinded phase III trial to assess the efficacy and tolerability of fulvestrant (Faslodex) injection. The Evaluation of Faslodex vs. Exemestane Clinical Trial aims to enroll 660 postmenopausal women with hormone receptor--positive metastatic breast cancer in the U.S. and worldwide. Contact AstraZeneca, 866-992-9276.

Return to Faslodex

Home

Contact

Resources

Exchange Links

ebay